A novel metabolic pathway for benzothiadiazoles; X-ray molecular structure of 5-chloro-4-(4,5-dihydroimidazol-2-ylamino)-1,3-dimethyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide

Abstract

The methylated derivative of the major metabolite of sirdalud [5-chloro-4-(4,5-dihydroimidazol-2-ylamino)-2,1,3-benzothiadiazole hydrochloride] has been examined by X-ray crystallography. The structure confirms the existence of a new metabolic pathway. A comparison of the structure with that of a number of α2-adrenergic drugs is made.